{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:39:27Z","timestamp":1787841567415,"version":"build-2784847793"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Scoring systems play a crucial role in dermatology by providing objective measurements of disease severity, treatment efficacy, and outcome comparisons. In autoimmune blistering diseases (AIBDs), standardized scoring systems are essential for accurate evaluations; however, there is currently a lack of consensus on scoring methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This literature review explores scoring systems in AIBDs by tracing their development, addressing challenges, and highlighting their role in defining endpoints, regulatory considerations, and clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Existing scoring systems for AIBDs, such as the Pemphigus Disease Area Index, Autoimmune Bullous Skin Disorder Intensity Score, Pemphigus Oral Lesions Intensity Score, Oral Disease Severity Score, and Pemphigus Vulgaris Activity Score, are examined for their validity, reliability, and responsiveness. The Bullous Pemphigoid Disease Area Index for bullous pemphigoid is also discussed. The concept of minimal clinically important differences is explored to determine clinically significant improvements in disease severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This review provides a comprehensive understanding of the central role of scoring systems in dermatology and their implications for research and clinical practice in AIBDs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_611_23","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T02:30:55Z","timestamp":1724121055000},"page":"732-738","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Scoring Criteria for Autoimmune Bullous Diseases: Utility, Merits, and Demerits"],"prefix":"10.4103","volume":"15","author":[{"given":"Henry","family":"Tseng","sequence":"first","affiliation":[{"name":"Department of Dermatology, St. George Hospital, Sydney, NSW, Australia"},{"name":"Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Stone","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St. George Hospital, Sydney, NSW, Australia"},{"name":"Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9d\u00e9e F.","family":"Murrell","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St. George Hospital, Sydney, NSW, Australia"},{"name":"Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/jdv.15679","article-title":"Review of autoimmune blistering diseases: The Pemphigoid diseases","volume":"33","author":"Daniel","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"R3-20240830","first-page":"42","article-title":"Disease severity scoring systems in dermatology","volume":"50","author":"Bila\u00e7","year":"2016","journal-title":"Turkderm-Turk Arch Dermatol Venereol"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijwd.2016.10.003","article-title":"Validation studies of outcome measures in pemphigus","volume":"2","author":"Hanna","year":"2016","journal-title":"Int J Womens Dermatol"},{"key":"R5-20240830","first-page":"E37","article-title":"Skin scores: A review of clinical scoring systems in dermatology","volume":"104","author":"Mazori","year":"2019","journal-title":"Cutis"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1590\/bjpt-rbf.2014.0143","article-title":"The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) and how to select an outcome measurement instrument","volume":"20","author":"Mokkink","year":"2016","journal-title":"Braz J Phys Ther"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jclinepi.2010.02.006","article-title":"The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes","volume":"63","author":"Mokkink","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3390\/jpm12071167","article-title":"The Meaning and reliability of minimal important differences (MIDs) for clinician-reported outcome measures (ClinROMs) in dermatology-A scoping review","volume":"12","author":"Speeckaert","year":"2022","journal-title":"J Pers Med"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"1243581","DOI":"10.3389\/fimmu.2023.1243581","article-title":"Precision in treatment evaluation: Importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases","volume":"14","author":"Tseng","year":"2023","journal-title":"Front Immunol"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clindermatol.2011.03.017","article-title":"Severity score indexes for blistering diseases","volume":"30","author":"Daniel","year":"2012","journal-title":"Clin Dermatol"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bjd.14562","article-title":"Quantifying disease extent in pemphigus","volume":"175","author":"Payne","year":"2016","journal-title":"Br J Dermatol"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/1346-8138.12649","article-title":"Grading criteria for disease severity by pemphigus disease area index","volume":"41","author":"Shimizu","year":"2014","journal-title":"J Dermatol"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjd.14405","article-title":"Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus","volume":"175","author":"Boulard","year":"2016","journal-title":"Br J Dermatol"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/bjd.19718","article-title":"Establishing cut-off values for mild, moderate and severe disease in patients with pemphigus using the Pemphigus Disease Area Index","volume":"184","author":"Krain","year":"2021","journal-title":"Br J Dermatol"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1111\/odi.14713","article-title":"Pemphigus disease and area index: Unmet needs in the real-world management of pemphigus","volume":"30","author":"Mahmoudi","year":"2024","journal-title":"Oral Dis"},{"key":"R16-20240830","first-page":"4","article-title":"Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus","volume":"17","author":"Pfutze","year":"2007","journal-title":"Eur J Dermatol"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12895-020-00105-y","article-title":"Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies","volume":"20","author":"Mohebi","year":"2020","journal-title":"BMC Dermatol"},{"key":"R18-20240830","first-page":"224","article-title":"Pemphigus vulgaris activity score and assessment of convergent validity","volume":"51","author":"Chams-Davatchi","year":"2013","journal-title":"Acta Med Iran"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/jid.2009.72","article-title":"Reliability and convergent validity of two outcome instruments for pemphigus","volume":"129","author":"Rosenbach","year":"2009","journal-title":"J Invest Dermatol"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large international validation of ABSIS and PDAI pemphigus severity scores","volume":"139","author":"Hebert","year":"2019","journal-title":"J Invest Dermatol"},{"key":"R21-20240830","first-page":"158","article-title":"Pemphigus area and activity score (PAAS)--a novel clinical scoring method for monitoring of pemphigus vulgaris patients","volume":"37","author":"Agarwal","year":"1998","journal-title":"Int J Dermatol"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0019-5154.80403","article-title":"Scoring systems in pemphigus","volume":"56","author":"Grover","year":"2011","journal-title":"Indian J Dermatol."},{"key":"R23-20240830","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2340\/00015555-2473","article-title":"The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: Which one to use?","volume":"97","author":"Wijayanti","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"R24-20240830","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/bjd.19611","article-title":"International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid","volume":"184","author":"Masmoudi","year":"2021","journal-title":"Br J Dermatol"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","article-title":"Definitions and outcome measures for mucous membrane pemphigoid: Recommendations of an international panel of experts","volume":"72","author":"Murrell","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fmed.2020.00449","article-title":"Pemphigus oral lesions intensity score (POLIS): A novel scoring system for assessment of severity of oral lesions in pemphigus vulgaris","volume":"7","author":"Sindhuja","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R27-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.25259\/IJDVL_592_2021","article-title":"Disease severity scores in dermatology: An update of the various indices","author":"Chakraborty","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R28-20240830","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/bjd.16265","article-title":"An oral disease severity score validated for use in oral pemphigus vulgaris","volume":"179","author":"Ormond","year":"2018","journal-title":"Br J Dermatol"},{"key":"R29-20240830","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1365-2133.2007.08106.x","article-title":"A scoring system for mucosal disease severity with special reference to oral lichen planus","volume":"157","author":"Escudier","year":"2007","journal-title":"Br J Dermatol"},{"key":"R30-20240830","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00417-011-1853-z","article-title":"Ocular and oral grading of mucous membrane pemphigoid","volume":"250","author":"Reeves","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R31-20240830","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2133.2012.10882.x","article-title":"Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: A retrospective review of 10 patients","volume":"167","author":"Wee","year":"2012","journal-title":"Br J Dermatol"},{"key":"R32-20240830","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/ced.12842","article-title":"Crescendo response to rituximab in oral pemphigus vulgaris: A case with 7-year follow-up","volume":"41","author":"Greenblatt","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"R33-20240830","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-4362.2003.01811.x","article-title":"A new grading system for oral pemphigus","volume":"42","author":"Saraswat","year":"2003","journal-title":"Int J Dermatol"},{"key":"R34-20240830","first-page":"159","article-title":"Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent","volume":"18","author":"Esmaili","year":"2008","journal-title":"Eur J Dermatol"},{"key":"R35-20240830","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels","volume":"144","author":"Harman","year":"2001","journal-title":"Br J Dermatol"},{"key":"R36-20240830","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/0378-6323.25780","article-title":"Study of desmoglein 1 and 3 antibody levels in relation to disease severity in Indian patients with pemphigus","volume":"72","author":"Kumar","year":"2006","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R37-20240830","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-4632.2005.02218.x","article-title":"Twelve-year clinico-therapeutic experience in pemphigus: A retrospective study of 54 cases","volume":"44","author":"Mahajan","year":"2005","journal-title":"Int J Dermatol"},{"key":"R38-20240830","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjd.17791","article-title":"Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: A pooled analysis of data from two phase III trials","volume":"181","author":"Silverberg","year":"2019","journal-title":"Br J Dermatol"},{"key":"R39-20240830","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/bjd.18037","article-title":"Time to get rid of the Investigator's Global Assessment as the primary outcome for clinical trials in atopic dermatitis?","volume":"181","author":"Bruin-Weller","year":"2019","journal-title":"Br J Dermatol"},{"key":"R40-20240830","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamadermatol.2013.4972","article-title":"Development of a quality-of-life instrument for autoimmune bullous disease: The Autoimmune Bullous Disease Quality of Life questionnaire","volume":"149","author":"Sebaratnam","year":"2013","journal-title":"JAMA Dermatol"},{"key":"R41-20240830","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/TJD.TJD_16_19","article-title":"Quality of life in Turkish patients with autoimmune blistering diseases: Reliability and validity of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires","volume":"13","author":"Bilgic-Temel","year":"2019","journal-title":"Turk J Dermatol"},{"key":"R42-20240830","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/bjd.19173","article-title":"Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scores","volume":"183","author":"Ferries","year":"2020","journal-title":"Br J Dermatol"},{"key":"R43-20240830","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.advms.2016.07.002","article-title":"Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease\u2013specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires","volume":"62","author":"Kalinska-Bienias","year":"2017","journal-title":"Adv Med Sci"},{"key":"R44-20240830","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2340\/00015555-2737","article-title":"Quality of life in Greek patients with autoimmune bullous diseases assessed with ABQOL and TABQOL indexes","volume":"97","author":"Patsatsi","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"R45-20240830","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1590\/abd1806-4841.20197198","article-title":"Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases'patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires","volume":"94","author":"Saleh","year":"2019","journal-title":"An Bras Dermatol"},{"key":"R46-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12955-017-0594-z","article-title":"Reliability and validity of the Chinese version of the autoimmune bullous disease quality of life (ABQOL) questionnaire","volume":"15","author":"Yang","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"R47-20240830","first-page":"YC01","article-title":"Dermatology specific quality of life in vitiligo patients and its relation with various variables: A hospital based cross-sectional study","volume":"8","author":"Mishra","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"R48-20240830","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.3389\/fimmu.2019.02571","article-title":"Assessing the correlation between disease severity indices and quality of life measurement tools in pemphigus","volume":"10","author":"Krain","year":"2019","journal-title":"Front Immunol"},{"key":"R49-20240830","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjd.19625","article-title":"Identifying the required degree of disease clearance to improve quality of life in pemphigus vulgaris","volume":"184","author":"Bax","year":"2021","journal-title":"Br J Dermatol"},{"key":"R51-20240830","doi-asserted-by":"crossref","first-page":"152010","DOI":"10.1016\/j.semarthrit.2022.152010","article-title":"The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time","volume":"55","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"R52-20240830","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jdin.2021.09.003","article-title":"Evaluation of the toxicity of glucocorticoids in patients with autoimmune blistering disease using the Glucocorticoid Toxicity Index: A cohort study","volume":"6","author":"Liang","year":"2022","journal-title":"JAAD Int"},{"key":"R53-20240830","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.34067\/KID.0000502021","article-title":"Glucocorticoid therapy in ANCA vasculitis: Using the glucocorticoid toxicity index as an outcome measure","volume":"2","author":"Floyd","year":"2021","journal-title":"Kidney360"},{"key":"R54-20240830","year":"2022"},{"key":"R55-20240830","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_611_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:02:06Z","timestamp":1787839326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_611_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_611_23","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"2023-08-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}